Sell Promis Neurosciences, Mackie Research says

Elliot Goldstein
An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his rating for Promis Neurosciences (Promis Neurosciences Stock Quote, Chart TSX:PMN) from “Speculative Buy” to “Sell” in a client update on Thursday.

A Phase III trial conducted by American biotech company Biogen and Japanese pharma company Eisai on antibody aducanumab in patients with mild cognitive impairment due to Alzheimer’s and mild Alzheimer’s disease dementia has been discontinued due to a futility analysis conducted by an independent data monitoring committee.

Uddin says the results will hit Promis Neurosciences’ share price hard, as he expects that Promis will not advance its own lead antibody candidate PMN310 into Phase I trials as previously planned.

______________________________________________________
An Engine for MedTech Innovation

This article is brought to you by Relay Medical Corp. (CSE:RELA)

 

 

Relay Medical is an integrated incubator/accelerator platform, developing a portfolio of medical technologies for pre-commercial exits in the Healthtech marketplace. Click on the logo for more info on this up-and-coming company…

 

___________________________________________________________

“This is a major setback for Alzheimer’s disease as aducanumab had shown very promising data earlier,” says Uddin. “Every single drug candidate targeting beta-amyloid has now failed. Based on this recent news we do not expect Promis to advance PMN310 into Phase I trials later this year– it simply would not make sense to do so, given all the failures with drug candidates targeting beta amyloid.”

“Promis does have some great early stage drug candidates. However, Promis’ PMN310 (lead drug candidate) is in significant jeopardy of being dropped from development, we thus expect PMN could take some time before a new drug candidate is ready for human trials,” he says.

Uddin has reduced his target price from $0.50 to $0.10, which represents a projected 12-month return of negative 74 per cent at the time of publication.

Tagged with: pmn
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you sell your Transat stock?

Persistently high fuel prices and growing pressure on Transat A.T.’s (Transat A.T. Stock Quote, Chart, News, Analysts, Financials TSX:TRZ) balance… [Read More]

2 hours ago

Analyst explains why Target may remain uncompetitive

Target’s (Target Corporation Stock Quote, Chart, News, Analysts, Financials NYSE:TGT) stronger-than-expected third-quarter results and improved earnings outlook have failed to… [Read More]

5 hours ago

Is Propel Holdings (TSX:PRL) undervalued?

Propel Holdings’ (Propel Holdings Stock Quote, Chart, News, Analysts, Financials TSX:PRL) expanding lending platform and use of artificial intelligence to… [Read More]

6 hours ago

This investor loves Digital Realty Trust

Digital Realty Trust (Digital Realty Trust Stock Quote, Chart, News, Analysts, Financials NYSE:DLR) offers investors exposure to growing artificial intelligence… [Read More]

7 hours ago

Quebecor has a 25% chance of acquiring Telus, analyst says

Quebecor’s (Quebecor Stock Quote, Chart, News, Analysts, Financials TSX:QBR.B) proposed $31-billion acquisition of Telus could transform the company into a… [Read More]

15 hours ago

Time to sell your Rapid Micro Biosystems stock?

Roth Capital Partners analyst Max Masucci downgraded Rapid Micro Biosystems (Rapid Micro Biosystems I Stock Quote, Chart, News, Analysts, Financials… [Read More]

15 hours ago